Enlivex Therapeutics Welcomes Matteo Renzi to Board, Paving the Way for Future Innovations

Enlivex Appoints Former Italian Prime Minister Matteo Renzi to Board of Directors

On November 24, 2025, Enlivex Therapeutics Ltd. (NASDAQ: ENLV) announced a significant enhancement to its leadership with the appointment of Matteo Renzi, the former Prime Minister of Italy, as a member of its board of directors. Renzi's extensive experience in politics, combined with his vision for innovative solutions, aligns with Enlivex's strategic direction as they venture into groundbreaking territory in the field of biotechnology.

Enlivex is a clinical-stage company specializing in macrophage reprogramming immunotherapy, a promising area that seeks to transform treatment methodologies for various diseases. Renzi's entry into the board is not just a formal position; it represents a commitment to steering the company towards innovative practices and leveraging emerging technologies, particularly in blockchain and predictive analytics. "I am thrilled to join Enlivex at such a historic moment. We need responsible innovation that can profoundly impact people's lives," Renzi stated, emphasizing the potential for biotechnology and blockchain technologies to revolutionize healthcare practices.

In addition to this exciting appointment, Enlivex made headlines with its recent announcement of a $212 million private placement. The funds raised from this offering will support the company's new treasury strategy focused on RAIN, a fully decentralized prediction market protocol. This initiative aims to combine the potential of predictive analytics with financial markets, allowing users to engage more meaningfully with financial decisions. The RAIN token will not only act as a governance tool for the protocol but is also designed to enhance liquidity and transparency in digital asset management.

Shai Novik, Chairman of the Board of Enlivex, expressed optimism regarding Renzi’s contribution: “His insight into global markets, governance, and public policy will be invaluable for us as we aim to increase shareholder value and innovate our services.” Renzi's focus on transparency and participation resonates with Enlivex's vision of democratizing access to health innovations and technological advancements.

Enlivex’s pipeline is particularly noteworthy as it features Allocetra™, an innovative therapy targeting osteoarthritis, a condition affecting millions worldwide. Current treatments largely focus on symptom management rather than reversing the disease's progression, highlighting a significant unmet need within the healthcare landscape. By aligning its pathways with blockchain technologies, Enlivex aims to not only improve treatment outcomes but also ensure that investors and patients remain informed and engaged in the therapeutic process.

Moreover, the private placement will enable Enlivex to strengthen its balance sheet while providing exposure to the burgeoning field of digital assets through its treasury reserves. This approach not only ensures that the company remains agile and responsive to market demands, but it also positions Enlivex as a leader among publicly traded biotech firms exploring treasury strategies within the digital asset landscape.

In conclusion, Matteo Renzi's appointment to the board of Enlivex is a pivotal moment for the company as it navigates the complexities of modern medicine and digital finance. By integrating innovative governance with robust scientific research and development, Enlivex Therapeutics stands poised to make substantial advancements in treatment methodologies while influencing the broader conversation around biotechnology and digital finance. As the company embarks on this next chapter, stakeholders will undoubtedly be keenly observing Enlivex's innovative trajectory.

About Enlivex

Enlivex Therapeutics combines the principles of biotechnology with cutting-edge digital asset strategies to redefine health care. With an unwavering commitment to transparency and patient-centric innovations, Enlivex serves as a beacon for both current stakeholders and future investors interested in bridging the gap between technology and therapeutic solutions.